Evidence map›Paper›PMID 32142554›Full record

ArticlePLoS pathogens2020

Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance.

Kelsey J Yamada, Cortney E Heim, Xinyuan Xi, Kuldeep S Attri, Dezhen Wang, Wenting Zhang, Pankaj K Singh, Tatiana K Bronich, Tammy Kielian

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Biofilm-host immunometabolic crosstalk inFrontiers in immunology · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  17. Article
  18. Pathogens (Basel, Switzerland) · 2025
    Review
  19. Article
  20. Implant-DerivedAntibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kelsey J YamadaDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0003-1071-8836
Cortney E HeimDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Xinyuan XiDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0003-3272-1761
Kuldeep S AttriEppley Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Dezhen WangEppley Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Wenting ZhangDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0002-6406-5220
Pankaj K SinghEppley Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Tatiana K BronichDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0003-4192-8422
Tammy KielianDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.ORCID 0000-0001-7624-670X
University of Nebraska Medical Center · US

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0M
The S. aureus biofilm lifecycleP01AI083211 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BAYLES, KENNETH W. · 2009 to 2023
$32.1M
Nebraska Center for Nanomedicine- Pilot ProjectsP30GM127200 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2018 to 2022
$5.7M
UNMC Histology/Imaging and Creighton University Imaging Core FacilityP30GM110768 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SMITH, SHELLEY D · 2014 to 2018
$5.1M
Targeted Core Shell Nanogels for Triple Negative Breast CancerU01CA198910 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BRONICH, TATIANA K, KABANOV, ALEXANDER V · 2015 to 2019
$2.8M
NCI NIH HHS P30 CA036727NCI NIH HHS U01 CA198910NIAID NIH HHS P01 AI083211NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P30 GM110768NIGMS NIH HHS P30 GM127200
6 · The paper itself

Abstract

Biofilm-associated prosthetic joint infections (PJIs) cause significant morbidity due to their recalcitrance to immune-mediated clearance and antibiotics, with Staphylococcus aureus (S. aureus) among the most prevalent pathogens. We previously demonstrated that S. aureus biofilm-associated monocytes are polarized to an anti-inflammatory phenotype and the adoptive transfer of pro-inflammatory macrophages attenuated biofilm burden, highlighting the critical role of monocyte/macrophage inflammatory status in dictating biofilm persistence. The inflammatory properties of leukocytes are linked to their metabolic state, and here we demonstrate that biofilm-associated monocytes exhibit a metabolic bias favoring oxidative phosphorylation (OxPhos) and less aerobic glycolysis to facilitate their anti-inflammatory activity and biofilm persistence. To shift monocyte metabolism in vivo and reprogram cells to a pro-inflammatory state, a nanoparticle approach was utilized to deliver the OxPhos inhibitor oligomycin to monocytes. Using a mouse model of S. aureus PJI, oligomycin nanoparticles were preferentially internalized by monocytes, which significantly reduced S. aureus biofilm burden by altering metabolism and promoting the pro-inflammatory properties of infiltrating monocytes as revealed by metabolomics and RT-qPCR, respectively. Injection of oligomycin alone had no effect on monocyte metabolism or biofilm burden, establishing that intracellular delivery of oligomycin is required to reprogram monocyte metabolic activity and that oligomycin lacks antibacterial activity against S. aureus biofilms. Remarkably, monocyte metabolic reprogramming with oligomycin nanoparticles was effective at clearing established biofilms in combination with systemic antibiotics. These findings suggest that metabolic reprogramming of biofilm-associated monocytes may represent a novel therapeutic approach for PJI.

Indexed as

AnimalsBiofilmsCellular ReprogrammingImplants, ExperimentalInflammationMiceMonocytesOligomycinsOxidative PhosphorylationStaphylococcal InfectionsStaphylococcus aureusOligomycins

Identifiers

PMID32142554
PMCPMC7080272
OpenAlexW3010465594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.